Marksans Pharma soars after its arm secures marketing authorization for three products

21 Aug 2024 Evaluate

Marksans Pharma is currently trading at Rs. 223.30, up by 2.40 points or 1.09% from its previous closing of Rs. 220.90 on the BSE.

The scrip opened at Rs. 220.05 and has touched a high and low of Rs. 224.95 and Rs. 218.45 respectively. So far 180885 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 224.95 on 21-Aug-2024 and a 52 week low of Rs. 93.85 on 18-Sep-2023.

Last one week high and low of the scrip stood at Rs. 224.95 and Rs. 207.35 respectively. The current market cap of the company is Rs. 10182.59 crore.

The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 22.34% and 33.78% respectively.

Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization from UKMHRA for the three products. These products are Fluoxetine 10mg Capsules, Fluoxetine 30mg Capsules and Fluoxetine 60mg Capsules. 

Earlier, the USFDA had issued an Establishment Inspection Report (EIR) for the manufacturing facility of Marksans Pharma located at Verna Industrial estate, Verna, Goa, India.  

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.


Marksans Pharma Share Price

307.35 -1.65 (-0.53%)
22-Nov-2024 16:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1215.35
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 947.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.